A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 7325; AZD 7325
- Indications Anxiety disorders
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 29 Sep 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jul 2009 New trial record